{"id":47820,"date":"2024-07-31T08:53:30","date_gmt":"2024-07-31T08:53:30","guid":{"rendered":"https:\/\/ibima.eu\/?p=47820"},"modified":"2024-07-31T08:53:31","modified_gmt":"2024-07-31T08:53:31","slug":"omics-integration-for-precision-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/omics-integration-for-precision-cancer-immunotherapy\/","title":{"rendered":"Omics integration for precision cancer immunotherapy"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row column_structure=\u00bb3_5,2_5&#8243; _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p><span style=\"color: #000000;\"><strong>Financed by<\/strong>\u00a0: European Commission<\/span><\/p>\n<p><strong><span><span class=\"goog-text-highlight\"><span style=\"color: #000000;\">Grant Agreement ID:\u00a0<\/span>\u00a0<\/span><\/span><\/strong><a href=\"https:\/\/cordis.europa.eu\/project\/id\/799818\"><span>799818<\/span><\/a><\/p>\n<p><span style=\"color: #000000;\"><strong>Program<\/strong>\u00a0: H2020- Call: International Mobility of Researchers \u2013 MSCA \u2013 IF 2017<\/span><\/p>\n<p><span style=\"color: #000000;\"><b><span class=\"\">Duration:<\/span><\/b><span class=\"\">\u00a0\u00a0January 2018 to February 2020<\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><\/span><\/p>\n<p><span style=\"color: #000000;\">Beneficiary: Barrag\u00e1n Mallofret, Isabel<\/span><\/p>\n<p><span style=\"color: #000000;\">Supervisor: Alba, Emilio<\/span><\/p>\n<p><span style=\"color: #000000;\">Implementation center:<\/span> <a href=\"https:\/\/www.huvv.es\/\">Hospital Universitario Virgen de la Victoria<\/a><\/p>\n<p><span style=\"color: #000000;\">Research group of IBIMA involved: Clinical and translational research in Cancer<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb2_5&#8243; _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_post_title title=\u00bboff\u00bb meta=\u00bboff\u00bb admin_label=\u00bbT\u00edtulo de publicaci\u00f3n\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bbArial||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#2ea3f2&#8243; title_font_size=\u00bb35px\u00bb background_color=\u00bbRGBA(255,255,255,0)\u00bb text_orientation=\u00bbcenter\u00bb width=\u00bb100%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb1%||1%||false|false\u00bb title_font_size_last_edited=\u00bboff|desktop\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb305.4px\u00bb custom_margin=\u00bb-16px||||false|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbABSTRACT\u00bb _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3&#8243; locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3acc1b5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3acc1b5\" data-element_type=\"section\">\n<div class=\"elementor-container elementor-column-gap-default\">\n<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f4bbc10\" data-id=\"f4bbc10\" data-element_type=\"column\">\n<div class=\"elementor-widget-wrap elementor-element-populated\">\n<div class=\"elementor-element elementor-element-89d6f88 elementor-widget elementor-widget-text-editor\" data-id=\"89d6f88\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n<div class=\"elementor-widget-container\">\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The development of immunotherapies based on checkpoint inhibitors marks the beginning of a new era in the treatment of cancer, with 20-30% of tumor response in advanced non\u2013small-cell lung cancer and melanoma. However, the rational use of these agents has been limited by the lack of definitive predictive biomarkers.<\/span><br \/><span style=\"color: #000000;\">The recent \u201comics revolution\u201d provides great opportunities to elucidate the biological processes linked to the treatment outcome. Here we propose a multilayer integrative omics analysis using transcriptomics and genetic and epigenetic mapping, together with detection of specific immunologic proteins, to identify biomarkers of clinical response to immunotherapy amenable to be used in liquid biopsies.<\/span><br \/><span style=\"color: #000000;\">Objective: to identify definite biomarkers predictive of the response to anti-PD-1, anti-PD-L1, and anti-CTLA4 therapy in patients with metastatic melanoma and advanced non\u2013small-cell lung cancer. We structure the proposal in two parts:<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">WP1. Signature of response to the immunotherapy by integrating transcriptomics and genetic and epigenetic mapping in tumor tissues: solid biopsy. Genome-wide transcriptomics on FAC-sorted tumor and stroma cells followed by targeted genetic and epigenetic mapping in the differentially expressed genes in responders.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">WP2: Identification of circulating biomarkers of response to the immunotherapy: liquid biopsy. Pre- and post-treatment blood samples from a validation cohort will be used as liquid biopsy. Genetic and epigenetic biomarkers of WP1 will be tested as circulating biomarkers. In addition, LINE-1 methylation, total Circulating Tumor Cells, CD56+, or CD8+ PD-1+ cells will be tested.<\/span><br \/><span style=\"color: #000000;\">This project applies multiple innovative approaches to address the urgent need of identifying biomarkers of clinical response to immunotherapy in cancer, amenable to be used non-invasively. In line with the Horizon 2020 Research &amp; Innovation goal, we will \u201cimprove our ability to monitor health and to prevent, detect, treat and manage disease.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Financed by\u00a0: European Commission Grant Agreement ID:\u00a0\u00a0799818 Program\u00a0: H2020- Call: International Mobility of Researchers \u2013 MSCA \u2013 IF 2017 Duration:\u00a0\u00a0January 2018 to February 2020 Beneficiary: Barrag\u00e1n Mallofret, Isabel Supervisor: Alba, Emilio Implementation center: Hospital Universitario Virgen de la Victoria Research group of IBIMA involved: Clinical and translational research in Cancer The development of immunotherapies based [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":47824,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2193],"tags":[],"class_list":["post-47820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recursos-humanos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Omics integration for precision cancer immunotherapy - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/omics-integration-for-precision-cancer-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omics integration for precision cancer immunotherapy - Ibima\" \/>\n<meta property=\"og:description\" content=\"Financed by\u00a0: European Commission Grant Agreement ID:\u00a0\u00a0799818 Program\u00a0: H2020- Call: International Mobility of Researchers \u2013 MSCA \u2013 IF 2017 Duration:\u00a0\u00a0January 2018 to February 2020 Beneficiary: Barrag\u00e1n Mallofret, Isabel Supervisor: Alba, Emilio Implementation center: Hospital Universitario Virgen de la Victoria Research group of IBIMA involved: Clinical and translational research in Cancer The development of immunotherapies based [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/omics-integration-for-precision-cancer-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T08:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-31T08:53:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"394\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Omics integration for precision cancer immunotherapy\",\"datePublished\":\"2024-07-31T08:53:30+00:00\",\"dateModified\":\"2024-07-31T08:53:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/\"},\"wordCount\":629,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/IMMUNOMARK-logo.jpg\",\"articleSection\":[\"Recursos humanos\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/\",\"name\":\"Omics integration for precision cancer immunotherapy - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/IMMUNOMARK-logo.jpg\",\"datePublished\":\"2024-07-31T08:53:30+00:00\",\"dateModified\":\"2024-07-31T08:53:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/IMMUNOMARK-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/IMMUNOMARK-logo.jpg\",\"width\":1920,\"height\":394,\"caption\":\"IMMUNOMARK logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/omics-integration-for-precision-cancer-immunotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omics integration for precision cancer immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omics integration for precision cancer immunotherapy - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/omics-integration-for-precision-cancer-immunotherapy\/","og_locale":"en_GB","og_type":"article","og_title":"Omics integration for precision cancer immunotherapy - Ibima","og_description":"Financed by\u00a0: European Commission Grant Agreement ID:\u00a0\u00a0799818 Program\u00a0: H2020- Call: International Mobility of Researchers \u2013 MSCA \u2013 IF 2017 Duration:\u00a0\u00a0January 2018 to February 2020 Beneficiary: Barrag\u00e1n Mallofret, Isabel Supervisor: Alba, Emilio Implementation center: Hospital Universitario Virgen de la Victoria Research group of IBIMA involved: Clinical and translational research in Cancer The development of immunotherapies based [&hellip;]","og_url":"https:\/\/ibima.eu\/en\/omics-integration-for-precision-cancer-immunotherapy\/","og_site_name":"Ibima","article_published_time":"2024-07-31T08:53:30+00:00","article_modified_time":"2024-07-31T08:53:31+00:00","og_image":[{"width":1920,"height":394,"url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg","type":"image\/jpeg"}],"author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Omics integration for precision cancer immunotherapy","datePublished":"2024-07-31T08:53:30+00:00","dateModified":"2024-07-31T08:53:31+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/"},"wordCount":629,"commentCount":0,"image":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg","articleSection":["Recursos humanos"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/","url":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/","name":"Omics integration for precision cancer immunotherapy - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg","datePublished":"2024-07-31T08:53:30+00:00","dateModified":"2024-07-31T08:53:31+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#primaryimage","url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg","contentUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/07\/IMMUNOMARK-logo.jpg","width":1920,"height":394,"caption":"IMMUNOMARK logo"},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/omics-integration-for-precision-cancer-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Omics integration for precision cancer immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/47820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=47820"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/47820\/revisions"}],"predecessor-version":[{"id":47828,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/47820\/revisions\/47828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media\/47824"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=47820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=47820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=47820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}